Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against SFBC International, Inc.

If you wish to serve as lead plaintiff, you must move the Court nolater than 60 days from January 3, 2006. If you wish to discuss thisaction or have any questions concerning this notice or your rights orinterests, please contact plaintiff's counsel, William Lerach orDarren Robbins of Lerach Coughlin at 800/449-4900 or 619/231-1058, orvia e-mail at wsl@lerachlaw.com. If you are a member of this class,you can view a copy of the complaint as filed or join this classaction online at http://www.lerachlaw.com/cases/sfbc/. Any member ofthe purported class may move the Court to serve as lead plaintiffthrough counsel of their choice, or may choose to do nothing andremain an absent class member.

The complaint charges SFBC and certain of its officers anddirectors with violations of the Securities Exchange Act of 1934. SFBCis a drug development services company, which provides a range ofearly and late stage clinical drug development services to brandedpharmaceutical, biotechnology, generic drug, and medical devicecompanies worldwide.

The complaint alleges that throughout the Class Period, defendantsmade materially false and misleading statements regarding theCompany's business and prospects, including that it was achievingrecord results from its worldwide recognition as a top drugdevelopment services company. As a result of the defendants' falsestatements, SFBC stock traded at inflated levels during the ClassPeriod, whereby the Company's top officers and directors sold morethan $29 million worth of their own shares together with assisting theCompany to sell more than $326 million worth of the Company shares inthree separate offerings.

On November 2, 2005, however, Bloomberg ran an article revealingthe true nature of the Company's business. The article revealed, amongother things, that, in order to insure that it had enough participantsfor its drug testing contracts, the Company provided inadequatedisclosures in its consent forms regarding the dangers of particulartests, and that the Company had manipulated participants vis-a-vis itscompensation payments to assure its participants would not drop out ofa drug testing trial or report uncomfortable or adverse reactions to adrug. In a related article on November 16, 2005, Bloomberg reportedthat the Company's top officers and directors had confronted certainparticipants they believed to have been responsible for revealinginformation to Bloomberg and advised them that they would call theImmigration and Naturalization Service and have them deported unlessthey signed sworn statements containing false statements contradictingthose in the Bloomberg article.

Then, on December 15, 2005, SFBC announced the results of its own"internal investigation" of the allegations in the Bloomberg articles.According to the complaint, the "internal investigation" was actuallya concerted effort to "white-wash" the complicity of SFBC's seniorofficers and directors and failed to explain the defects in SFBC'srecruiting and administrative practices. From the day before Bloombergpublished its first article on November 2, 2005, through the end ofthe Class Period on December 15, 2005, SFBC's stock price fell from$41.49 to $15.78, a 61% drop.

Plaintiff seeks to recover damages on behalf of all purchasers ofSFBC publicly traded securities during the Class Period (the "Class").The plaintiff is represented by Lerach Coughlin, which has expertisein prosecuting investor class actions and extensive experience inactions involving financial fraud.

Lerach Coughlin, a 160-lawyer firm with offices in San Diego, SanFrancisco, Los Angeles, New York, Boca Raton, Washington, D.C.,Houston, Philadelphia and Seattle, is active in major litigationspending in federal and state courts throughout the United States andhas taken a leading role in many important actions on behalf ofdefrauded investors, consumers, and companies, as well as victims ofhuman rights violations. Lerach Coughlin lawyers have been responsiblefor more than $20 billion in aggregate recoveries. The Lerach CoughlinWeb site (http://www.lerachlaw.com) has more information about thefirm.